{"name":"ACADIA Pharmaceuticals","permalink":"acadia-pharmaceuticals","crunchbase_url":"http://www.crunchbase.com/company/acadia-pharmaceuticals","homepage_url":"http://www.acadia-pharm.com/","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"info@acadia-pharm.com","phone_number":"(858) 558-2871","description":"","created_at":"Wed Jan 12 04:19:20 UTC 2011","updated_at":"Wed Jan 12 04:20:51 UTC 2011","overview":"<p>ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinsonâ€™s disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimerâ€™s disease psychosis, for which it is initiating a Phase II feasibility study. </p>","image":{"available_sizes":[[[150,46],"assets/images/resized/0011/6927/116927v1-max-150x150.png"],[[163,50],"assets/images/resized/0011/6927/116927v1-max-250x250.png"],[[163,50],"assets/images/resized/0011/6927/116927v1-max-450x450.png"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"President and CEO","person":{"first_name":"Uli","last_name":"Hacksell","permalink":"uli-hacksell","image":null}},{"is_past":false,"title":"Executive Vice President, CFO","person":{"first_name":"Thomas","last_name":"H. Aasen","permalink":"thomas-h-aasen","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$15M","funding_rounds":[{"round_code":"unattributed","source_url":"https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=29&aid=DJFVLS0020110111e71b0002v&r=Rss&s=DJFVLS","source_description":"Public Acadia Pharma To Raise $15M From NEA, Venrock, Others ","raised_amount":15000000,"raised_currency_code":"USD","funded_year":2011,"funded_month":1,"funded_day":11,"investments":[{"company":null,"financial_org":{"name":"New Enterprise Associates","permalink":"new-enterprise-associates","image":{"available_sizes":[[[150,110],"assets/images/resized/0001/5083/15083v3-max-150x150.png"],[[150,110],"assets/images/resized/0001/5083/15083v3-max-250x250.png"],[[150,110],"assets/images/resized/0001/5083/15083v3-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Venrock","permalink":"venrock","image":{"available_sizes":[[[150,52],"assets/images/resized/0001/6279/16279v1-max-150x150.jpg"],[[250,87],"assets/images/resized/0001/6279/16279v1-max-250x250.jpg"],[[351,123],"assets/images/resized/0001/6279/16279v1-max-450x450.jpg"]],"attribution":null}},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"3911 Sorrento Valley Blvd","address2":"","zip_code":"92121 ","city":"San Diego","state_code":"CA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[],"ipo":{"valuation_amount":null,"valuation_currency_code":"USD","pub_year":null,"pub_month":null,"pub_day":null,"stock_symbol":"NASDAQ:ACAD"},"video_embeds":[],"screenshots":[],"external_links":[]}